Head-to-head · Cost-Efficiency Index
Boston Medical Group vs June Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Boston Medical Group
Cost-first shoppers who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate.
Visit Boston Medical GroupJune Health
Cost-first shoppers who want not clearly differentiated from other entry-level GLP-1 telehealth storefronts; caution warranted given its newness.
Visit June HealthThe verdict
Boston Medical Group and June Health tie on the Cost-Efficiency Index at 59/100, so neither wins outright on the numbers. For most shoppers we'd start with Boston Medical Group (ranked #269, a hair above #273) — Cost-first shoppers who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate. But June Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Boston Medical Group.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Boston Medical Group | June Health |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 59/100 |
| Semaglutide / mo | $199/mo (starting strength, rising with dose, compounded) | $199/mo (compounded) |
| Tirzepatide / mo | Not disclosed | $199/mo (compounded) |
| Semaglutide / yr (modeled) | $2,388 | $2,388 |
| Tirzepatide / yr (modeled) | — | $2,388 |
| Coverage | 7 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #269 | #273 |
Boston Medical Group
59/100Where the value is
- An established medical group with a defined 12-week program rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
The tradeoffs
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week program totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
June Health
59/100Where the value is
- Low advertised entry price ($199/mo)
- Claims licensed providers in all 50 states
- Real legal/policy pages present in the footer despite being a new site
The tradeoffs
- Very new operation -- domain reportedly registered only in May 2026
- No LegitScript badge or certification mention found anywhere on the site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.